女子急性単純性膀胱炎の126例に対し, OFLX 300mg 1日1回3日間投与と, 同薬100mg 1日3回3日間投与の比較検討をした。UTI薬効評価可能のそれぞれ, 42例と43例とでは, ともに総合臨床効果の98%を呈するなど, 自覚症状・膿尿・細菌尿に対する効果も主治医による効果判定にも, あるいは第7病日における再発検討にても, ほとんど両群に差をみとめなかった。自覚的副作用は両群あわせてもわずかに1.2%であり, 全例に臨検値を検討しなかったため, 概括安全度に対する検討は不十分であったA comparative study of ofloxacin (OFLX), a new oral quinolone, was carried out at the Department of Urology, Osaka University Hospital and its eighteen affiliated hospitals to evaluate the clinical efficacy and safety of daily dose of 300 mg, given either once daily dose (SID group), or in three divided doses (TID group), in the treatment of acute uncomplicated cystitis in women. Clinical efficacy was evaluated in 42 cases from the SID group, and 43 cases from TID group, respectively, according to the criteria by the Japanese UTI Committee. In the SID group, the clinical efficacy was evaluated as excellent in 29 cases, moderate in 12 and poor in 1, with an overall clinical effectiveness rate of 98%. In the TID group, it was evaluated as excellent in 25 cases, moderate in 17 and poor in 1, with an overall clinical effectiveness rate of 98%. Safety was monitored only by subjective complaints. In the SID group, no subjective side effects appeared (0%). In the TID group, one of the 43 women (2.3%) complained of borborygmus. These findings suggest that there was no significant difference between the two groups in the safety and efficacy of ofloxacin
